News
ADAPY
0.010
0.00%
0.000
Weekly Report: what happened at ADAPY last week (0302-0306)?
Weekly Report · 1d ago
Weekly Report: what happened at ADAPY last week (0223-0227)?
Weekly Report · 03/02 09:37
Weekly Report: what happened at ADAPY last week (0216-0220)?
Weekly Report · 02/23 09:36
Weekly Report: what happened at ADAPY last week (0209-0213)?
Weekly Report · 02/16 09:36
Weekly Report: what happened at ADAPY last week (0202-0206)?
Weekly Report · 02/09 09:37
Weekly Report: what happened at ADAPY last week (0126-0130)?
Weekly Report · 02/02 09:36
Weekly Report: what happened at ADAPY last week (0119-0123)?
Weekly Report · 01/26 09:37
Weekly Report: what happened at ADAPY last week (0112-0116)?
Weekly Report · 01/19 09:40
Weekly Report: what happened at ADAPY last week (0105-0109)?
Weekly Report · 01/12 09:39
Weekly Report: what happened at ADAPY last week (1229-0102)?
Weekly Report · 01/05 09:37
Weekly Report: what happened at ADAPY last week (1222-1226)?
Weekly Report · 12/29/2025 09:36
Weekly Report: what happened at ADAPY last week (1215-1219)?
Weekly Report · 12/22/2025 09:36
Weekly Report: what happened at ADAPY last week (1208-1212)?
Weekly Report · 12/15/2025 09:39
Weekly Report: what happened at ADAPY last week (1201-1205)?
Weekly Report · 12/08/2025 09:39
Weekly Report: what happened at ADAPY last week (1124-1128)?
Weekly Report · 12/01/2025 09:36
Weekly Report: what happened at ADAPY last week (1117-1121)?
Weekly Report · 11/24/2025 09:39
Adaptimmune Announces Changes to Board and Executive Leadership Team
Newsfile · 11/17/2025 12:30
Weekly Report: what happened at ADAPY last week (1110-1114)?
Weekly Report · 11/17/2025 09:39
Weekly Report: what happened at ADAPY last week (1103-1107)?
Weekly Report · 11/10/2025 09:38
Weekly Report: what happened at ADAPY last week (1027-1031)?
Weekly Report · 11/03/2025 09:37
More
Webull provides a variety of real-time ADAPY stock news. You can receive the latest news about Adaptimmune Therapeutics Plc through multiple platforms. This information may help you make smarter investment decisions.
About ADAPY
Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.